Literature DB >> 26417179

Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

George DeMaagd, Ashok Philip.   

Abstract

This second of five articles reviews Parkinson's disease pharmacotherapy, focusing on dopaminergic agents such as levodopa/carbidopa and dopamine receptor agonists.

Entities:  

Year:  2015        PMID： 26417179      PMCID： PMC4571848     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  108 in total

Review 1.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

Review 2.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

Authors:  Dien Dang; David Cunnington; John Swieca
Journal:  Clin Neuropharmacol       Date:  2011 Mar-Apr       Impact factor: 1.592

4.  Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

Authors:  A H Rajput
Journal:  Parkinsonism Relat Disord       Date:  2001-10       Impact factor: 4.891

Review 5.  Designing prodrugs for the treatment of Parkinson's disease.

Authors:  Piera Sozio; Laura Serafina Cerasa; Anna Abbadessa; Antonio Di Stefano
Journal:  Expert Opin Drug Discov       Date:  2012-04-12       Impact factor: 6.098

Review 6.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 7.  Levodopa in Parkinson's disease: from the past to the future.

Authors:  Gianni Pezzoli; Michela Zini
Journal:  Expert Opin Pharmacother       Date:  2010-03       Impact factor: 3.889

Review 8.  Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.

Authors:  Rebecca Stowe; Natalie Ives; Carl E Clarke; Kelly Handley; Alexandra Furmston; Katherine Deane; J J van Hilten; Keith Wheatley; Richard Gray
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

9.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

Authors:  David Okai; Sally Askey-Jones; Michael Samuel; Sean S O'Sullivan; K Ray Chaudhuri; Anne Martin; Joel Mack; Richard G Brown; Anthony S David
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

10.  The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.

Authors:  Julia Vaamonde; José M Flores; Roberto Weisser; Ramón Ibañez; José A Obeso
Journal:  Mov Disord       Date:  2009-04-15       Impact factor: 10.338
View more
  7 in total

1.  Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons.

Authors:  Nicola L Francis; Nanxia Zhao; Hannah R Calvelli; Astha Saini; Janace J Gifford; George C Wagner; Rick I Cohen; Zhiping P Pang; Prabhas V Moghe
Journal:  Tissue Eng Part A       Date:  2019-10-17       Impact factor: 3.845

2.  Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.

Authors:  Mariama S Azmy; Esther T Menze; Reem N El-Naga; Mariane G Tadros
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

4.  Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model.

Authors:  Pia Rivetti di Val Cervo; Roman A Romanov; Giada Spigolon; Débora Masini; Elisa Martín-Montañez; Enrique M Toledo; Gioele La Manno; Michael Feyder; Christian Pifl; Yi-Han Ng; Sara Padrell Sánchez; Sten Linnarsson; Marius Wernig; Tibor Harkany; Gilberto Fisone; Ernest Arenas
Journal:  Nat Biotechnol       Date:  2017-04-10       Impact factor: 54.908

Review 5.  Urinary Tract Infection in Parkinson's Disease.

Authors:  Elliot Hogg; Samuel Frank; Jillian Oft; Brian Benway; Mohammad Harun Rashid; Shouri Lahiri
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 6.  Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

Authors:  Jason Margolesky; Carlos Singer
Journal:  Ther Adv Neurol Disord       Date:  2017-10-30       Impact factor: 6.570

7.  Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.

Authors:  Emmanuel Vazquez-Mayorga; Mariana Grigoruta; Raul Dagda; Bridget Martinez; Ruben K Dagda
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.